Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vicore Pharma Holding ABOSTO:VICO -1.75%30 3-1 Month Momentum % is 18.81% as of Aug. 11, 2026. GuruFocus rates OSTO:VICO with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,385 Biotechnology companies, Vicore Pharma Holding AB ranks better than 83.32% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-11), Vicore Pharma Holding AB's 3-1 Month Momentum % is 18.81%.
The industry rank for Vicore Pharma Holding AB's 3-1 Month Momentum % or its related term are showing as below:
OSTO:VICO's 3-1 Month Momentum % is ranked better than 83.32% of 1385
companies
in the Biotechnology industry
Industry Median: -7.28
vs OSTO:VICO: 18.81
Vicore Pharma Holding AB (OSTO:VICO) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Vicore Pharma Holding AB 3-1 Month Momentum % Related Terms
OSTO:VICO vs VRTX, REGN, RVMD: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Vicore Pharma Holding AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vicore Pharma Holding AB 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Vicore Pharma Holding AB's 3-1 Month Momentum % falls into.
Vicore Pharma Holding AB (OSTO:VICO) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vicore Pharma Holding AB (OSTO:VICO) has a 3-1 Month Momentum % of 18.81% as of Aug. 11, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vicore Pharma Holding AB and its competitors. According to the industry distribution chart, Vicore Pharma Holding AB ranks #231 out of 1385 companies in the Biotechnology industry, placing it in the top 16.7%.
Is Vicore Pharma Holding AB's 3-1 Month Momentum % too high?
Vicore Pharma Holding AB's current 3-1 Month Momentum % is 18.81%. Based on the distribution chart, Vicore Pharma Holding AB ranks #231 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vicore Pharma Holding AB has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vicore Pharma Holding AB ranks #231 out of 1385 companies for 3-1 Month Momentum %. This places Vicore Pharma Holding AB in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current 3-1 Month Momentum % is 18.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (OSTO:VICO) has a current 3-1 Month Momentum % of 18.81%. The current 3-1 Month Momentum % is 18.81%. Vicore Pharma Holding AB's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Vicore Pharma Holding AB (OSTO:VICO), the current 3-1 Month Momentum % is 18.81% as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
30GF Score
Get the complete analysis for OSTO:VICO
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VICO has been successfully added to your 
